Mapping prodromal psychosis: A critical review of neuroimaging studies

European Psychiatry

Volumn 27, Issue 3, 2012, Pages 181-191

  Fusar Poli, P ^a   McGuire, P ^a   Borgwardt, S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

FMRI; Neuroimaging; PET; Prodromal; Psychosis; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE; GLUTAMIC ACID;

ANTERIOR CINGULATE; BRAIN SIZE; COGNITION; GRAY MATTER; HUMAN; INFERIOR TEMPORAL GYRUS; LIMBIC CORTEX; MEMORY; NEUROANATOMY; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SEPTUM PELLUCIDUM; SHORT SURVEY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUPERIOR TEMPORAL GYRUS; TASK PERFORMANCE; TEMPORAL LOBE;

BRAIN; DISEASE PROGRESSION; HUMANS; NEUROIMAGING; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 84858860084     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2011.06.006     Document Type: Short Survey

References (50)

1. Allen P., Seal M.L., Valli I., Fusar-Poli P., Perlini C., Day F., et al. Altered Prefrontal and Hippocampal Function During Verbal Encoding and Recognition in People With Prodromal Symptoms of Psychosis. Schizophr Bull 2011, 37(4):746-756.
2. Anis N.A., Berry S.C., Burton N.R., Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 1983, 79:565-575.
3. Bilder R.M., Reiter G., Bates J., Lencz T., Szeszko P., Goldman R.S., et al. Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol 2006, 28:270-282.
4. Borgwardt S.J., McGuire P.K., Aston J., Berger G., Dazzan P., Gschwandtner U., et al. Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. Br J Psychiatry Suppl 2007, 51:s69-s75.
5. Borgwardt S.J., Riecher-Rossler A., Dazzan P., Chitnis X., Aston J., Drewe M., et al. Regional gray matter volume abnormalities in the at-risk mental state. Biol Psychiatry 2007, 61:1148-1156.
6. Borgwardt S.J., McGuire P.K., Aston J., Gschwandtner U., Pfluger M.O., Stieglitz R.D., et al. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr Res 2008, 106:108-114.
7. Borgwardt S.J., Picchioni M.M., Ettinger U., Toulopoulou T., Murray R., McGuire P.K. Regional gray matter volume in monozygotic twins concordant and discordant for schizophrenia. Biol. Psychiatry 2010, 67:956-964.
8. Broome M.R., Matthiasson P., Fusar-Poli P., Woolley J., Johns L., Tabraham P., et al. Neural correlates of executive function and working memory in the "at-risk mental state" Br J Psychiatry 2009, 194:25-33.
9. Cahn W., Hulshoff Pol H.E., Lems E.B., van Haren N.E., Schnack H.G., van der Linden J.A., et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry 2002, 59:1002-1010.
10. Crossley NA, Mechelli A, Fusar-Poli P, Broome MR, Matthiasson P, Johns LC, et al. Superior temporal lobe dysfunction and fronto-temporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Hum Brain Mapp 2009;30(12):4129-37.
11. Fusar-Poli P., Perez J., Broome M., Borgwardt S., Placentino A., Caverzasi E., et al. Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci Biobehav Rev 2007, 31:465-484.
12. Fusar-Poli P., Allen P., McGuire P. Neuroimaging studies of the early stages of psychosis: a critical review. Eur Psychiatry 2008, 23:237-244.
13. Fusar-Poli P., Byrne M., Valmaggia L., Day F., Tabraham P., Johns L., et al. Social dysfunction preducts two years clinical outcomes in people at ultrahigh risk for psychosis. J Psychiatr Res 2009, 44:294-301.
14. Fusar-Poli P., Howes O.D., Allen P., Broome M., Valli I., Asselin M.C., et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry 2010, 67:683-691.
15. Fusar-Poli P., Broome M.R., Matthiasson P., Woolley J.B., Mechelli A., Johns L.C., et al. Prefrontal Function at Presentation Directly Related to Clinical Outcome in People at Ultrahigh Risk of Psychosis. Schizophr Bull 2011, 37(1):189-198.
16. Fusar-Poli P., Howes O.D., Allen P., Broome M., Valli I., Asselin M.C., et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 2011, 16(1):67-75.
17. Fusar-Poli P., Broome M., Woolley J., Johns L., Tabraham P., Bramon E., et al. Altered brain function directly related to structural abnormalities in people at ultra high risk of psychosis: longitudinal VBM-fMRI study. Journal of Psychiatric Research 2011, 45(2):190-198.
18. Fusar-Poli P., Borgwardt S., Crescini A., D'Este G., Kempton M., Lawrie S., et al. Neuroanatomical correlates of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci Biobehavioural Review 2011, 35(5):1175-1185.
19. Fusar-Poli P., Stone J.M., Broome M.R., Valli I., Mechelli A., McLean M.A., et al. Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Arch Gen Psychiatry 2011.
20. Gao X.M., Sakai K., Roberts R.C., Conley R.R., Dean B., Tamminga C.A. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 2000, 157:1141-1149.
21. Harrison P.J., Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005, 10:40-68.
22. Ho B.C., Andreasen N.C., Nopoulos P., Arndt S., Magnotta V., Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 2003, 60:585-594.
23. Hoff A.L., Svetina C., Shields G., Stewart J., DeLisi L.E. Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. Schizophr Res 2005, 78:27-34.
24. Honey C.R., Miljkovic Z., MacDonald J.F. Ketamine and phencyclidine cause a voltage-dependent block of responses to L-aspartic acid. Neurosci Lett 1985, 61:135-139.
25. Howes O.D., Montgomery A.J., Asselin M., Murray R., Grasby P., McGuire P. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry 2007, s51:s13-s18.
26. Howes O., Montgomery A., Asselin M., Valli I., Tabraham P., Johns L., et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009, 66:13-20.
27. Kasai K., Shenton M.E., Salisbury D.F., Hirayasu Y., Lee C.U., Ciszewski A.A., et al. Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. Am J Psychiatry 2003, 160:156-164.
28. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980, 20:379-382.
29. Kubicki M., Shenton M.E., Salisbury D.F., Hirayasu Y., Kasai K., Kikinis R., et al. Voxel-based morphometric analysis of gray matter in first-episode schizophrenia. Neuroimage 2002, 17:1711-1719.
30. Law A.J., Deakin J.F. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 2001, 12:2971-2974.
31. Lawrie S.M., McIntosh A.M., Hall J., Owens D.G., Johnstone E.C. Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. Schizophr Bull 2008, 34:330-340.
32. Mathalon D.H., Sullivan E.V., Lim K.O., Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 2001, 58:148-157.
33. Pantelis C., Velakoulis D., McGorry P.D., Wood S.J., Suckling J., Phillips L.J., et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003, 361:281-288.
34. Phillips L.J., McGorry P.D., Yung A.R., McGlashan T.H., Cornblatt B., Klosterkotter J. Pre-psychotic phase of schizophrenia and related disorders: recent progress and future opportunities. Br J Psychiatry Suppl 2005, 48:s33-s44.
35. Pilowsky L.S., Bressan R.A., Stone J.M., Erlandsson K., Mulligan R.S., Krystal J.H., et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 2006, 11:118-119.
36. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophr Res 2001, 49:1-52.
37. Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz R, Drewe J, et al. Neuroimaging predictors of transition to psychosis: a systematic review andmetaanalysis. Neurosci Biobehav Rev 2010;38(4):1207-22.
38. Sporn A.L., Greenstein D.K., Gogtay N., Jeffries N.O., Lenane M., Gochman P., et al. Progressive brain volume loss during adolescence in childhood-onset schizophrenia. Am J Psychiatry 2003, 160:2181-2189.
39. Steel R.M., Whalley H.C., Miller P., Best J.J., Johnstone E.C., Lawrie S.M. Structural MRI of the brain in presumed carriers of genes for schizophrenia, their affected and unaffected siblings. J Neurol Neurosurg Psychiatry 2002, 72:455-458.
40. Stone J.M., Day F., Tsagaraki H., Valli I., McLean M.A., Lythgoe D.J., et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry 2009, 66(6):533-539.
41. Suddath R.L., Christison G.W., Torrey E.F., Casanova M.F., Weinberger D.R. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N Engl J Med 1990, 322:789-794.
42. Sun D., Phillips L., Velakoulis D., Yung A., McGorry P., Wood S., et al. Progressive brain structural changes mapped as psychosis develops in "at-risk" individuals. Schizophr Res 2009, 108(1):85-92.
43. Theberge J., Williamson K.E., Aoyama N., Drost D.J., Manchanda R., Malla A.K., et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry 2007, 191:325-334.
44. Tibbo P., Hanstock C., Valiakalayil A., Allen P. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 2004, 161:1116-1118.
45. Trzesniak C., Oliveira I.R., Kempton M.J., Galvão-de Almeida A., Chagas M.H., Ferrari M.C., et al. Are cavum septum pellucidum abnormalities more common in schizophrenia spectrum disorders? A systematic review and meta-analysis. Schizophr Res 2011, 125:1-12.
46. Valli I., Stone J., Mechelli A., Bhattacharyya S., Raffin M., Allen P., et al. Altered medial temporal activation related to glutamate levels in subjects with prodromal signs of psychosis. Biol Psych 2011, 69(1):97-99.
47. Whalley H.C., Simonotto E., Moorhead W., McIntosh A., Marshall I., Ebmeier K.P., et al. Functional Imaging as a Predictor of Schizophrenia. Biol Psychiatry 2006, 60(5):454-462.
48. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000, 157:16-25.
49. Yung A.R., Phillips L.J., Yuen H.P., Francey S.M., McFarlane C.A., Hallgren M., et al. Psychosis prediction: 12-month follow-up of a high risk (" prodromal" ) group. Schizophr Res 2003, 60:21-32.
50. Yung A.R., Nelson B., Stanford C., Simmons M.B., Cosgrave E.M., Killackey E., et al. Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res 2008, 105:10-17.